Wedbush Comments on Unum Therapeutics Inc’s Q1 2020 Earnings (NASDAQ:UMRX)

Share on StockTwits

Unum Therapeutics Inc (NASDAQ:UMRX) – Stock analysts at Wedbush issued their Q1 2020 earnings per share (EPS) estimates for Unum Therapeutics in a research note issued to investors on Tuesday, November 5th. Wedbush analyst D. Nierengarten anticipates that the company will post earnings per share of ($0.20) for the quarter. Wedbush currently has a “Outperform” rating and a $13.00 target price on the stock. Wedbush also issued estimates for Unum Therapeutics’ Q2 2020 earnings at ($0.21) EPS, Q3 2020 earnings at ($0.23) EPS, Q4 2020 earnings at ($0.20) EPS, FY2022 earnings at ($1.44) EPS and FY2023 earnings at ($0.96) EPS.

A number of other brokerages also recently issued reports on UMRX. ValuEngine upgraded Unum Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. HC Wainwright restated a “buy” rating on shares of Unum Therapeutics in a research note on Tuesday, August 13th. Cowen restated a “hold” rating on shares of Unum Therapeutics in a research note on Monday, August 12th. Finally, Zacks Investment Research upgraded Unum Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 target price on the stock in a research note on Saturday. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Unum Therapeutics presently has a consensus rating of “Buy” and an average price target of $9.63.

Shares of Unum Therapeutics stock opened at $1.26 on Friday. Unum Therapeutics has a one year low of $1.22 and a one year high of $8.41. The stock has a 50 day moving average price of $1.47 and a 200-day moving average price of $2.29. The stock has a market cap of $39.55 million, a price-to-earnings ratio of -0.91 and a beta of 1.25. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.41 and a current ratio of 2.41.

Unum Therapeutics (NASDAQ:UMRX) last announced its earnings results on Monday, August 12th. The company reported ($0.34) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.39) by $0.05. The firm had revenue of $3.14 million during the quarter, compared to analysts’ expectations of $3.10 million. Unum Therapeutics had a negative return on equity of 75.60% and a negative net margin of 340.49%.

A number of hedge funds have recently made changes to their positions in the stock. Acadian Asset Management LLC grew its stake in Unum Therapeutics by 134.8% during the 2nd quarter. Acadian Asset Management LLC now owns 32,601 shares of the company’s stock worth $85,000 after buying an additional 18,717 shares during the last quarter. Tower Research Capital LLC TRC purchased a new position in Unum Therapeutics during the 3rd quarter worth $31,000. Susquehanna International Group LLP purchased a new position in Unum Therapeutics during the 2nd quarter worth $62,000. Wedbush Securities Inc. purchased a new position in Unum Therapeutics during the 3rd quarter worth $48,000. Finally, Jane Street Group LLC purchased a new position in Unum Therapeutics during the 2nd quarter worth $132,000. Hedge funds and other institutional investors own 42.07% of the company’s stock.

Unum Therapeutics Company Profile

Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company's lead product candidate is the ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ B cell non-Hodgkin lymphoma (r/r NHL).

Recommended Story: Options Trading – What is a Straddle?

Earnings History and Estimates for Unum Therapeutics (NASDAQ:UMRX)

Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.